Skye Bioscience (SKYE) Stock Price, News & Analysis

Company Overview

Skye Bioscience, Inc. is a clinical-stage biotechnology company focused on the development of novel, selective cannabinoid type 1 (CB1) receptor modulators for the treatment of ocular diseases. Headquartered in Sunnyvale, California, Skye Bioscience leverages proprietary chemistry and formulation expertise to design and optimize compounds with high potency, tissue selectivity and favorable drug-like properties. The company’s lead product candidate is being evaluated for the treatment of glaucoma and other ophthalmic conditions characterized by elevated intraocular pressure.

Skye Bioscience’s pipeline centers on synthetic cannabinoids engineered to avoid central nervous system side effects commonly associated with traditional cannabinoid therapies. By targeting CB1 receptors in ocular tissues, the company aims to deliver localized efficacy while minimizing systemic exposure. Preclinical studies have demonstrated promising pharmacokinetic and pharmacodynamic profiles, supporting the potential for twice-daily topical administration and rapid onset of action.

Founded in 2018, Skye Bioscience has assembled a multidisciplinary leadership team with expertise in pharmacology, medicinal chemistry and ophthalmology. The company collaborates with contract research organizations and academic partners to advance its clinical programs through regulatory milestones and into human trials. As a Nasdaq-listed entity under the symbol SKYE, Skye Bioscience is positioning itself at the forefront of cannabinoid-derived therapeutics for eye health.

Key Stats

• Today's Range: $3.76 to $4.09
• 50-Day Range: $3.14 to $4.58
• 52-Week Range: $1.14 to $7.11
• Volume: 558,714 shs
• Average Volume: 261,398 shs
• Market Capitalization: $123.96 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $15.50
• Consensus Rating: Buy

Skye Bioscience Stock Analysis - MarketRank™

Skye Bioscience scored higher than 46% of companies evaluated by MarketBeat, and ranked 649th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Buy

Consensus Rating

Skye Bioscience has received a consensus rating of Buy. The company's average rating score is 3.14, and is based on 6 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

Skye Bioscience has a consensus price target of $15.50, representing about 287.5% upside from its current price of $4.00.

Amount of Analyst Coverage

Skye Bioscience has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Skye Bioscience are expected to decrease in the coming year, from ($1.04) to ($1.18) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Skye Bioscience is -3.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Skye Bioscience is -3.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Skye Bioscience has a P/B Ratio of 1.78. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

14.95% of the float of Skye Bioscience has been sold short.

Short Interest Ratio / Days to Cover

Skye Bioscience has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Skye Bioscience has recently decreased by 1.48%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Skye Bioscience does not currently pay a dividend.

Dividend Growth

Skye Bioscience does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

14.95% of the float of Skye Bioscience has been sold short.

Short Interest Ratio / Days to Cover

Skye Bioscience has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Skye Bioscience has recently decreased by 1.48%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: 0.18

News Sentiment

Skye Bioscience has a news sentiment score of 0.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 9 news articles for Skye Bioscience this week, compared to 3 articles on an average week.

Search Interest

Only 6 people have searched for SKYE on MarketBeat in the last 30 days. This is a decrease of -65% compared to the previous 30 days.

MarketBeat Follows

6 people have added Skye Bioscience to their MarketBeat watchlist in the last 30 days. This is an increase of 20% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Skye Bioscience insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,601,097.00 in company stock.

Percentage Held by Insiders

Only 4.50% of the stock of Skye Bioscience is held by insiders.

Percentage Held by Institutions

Only 21.09% of the stock of Skye Bioscience is held by institutions.

SKYE Stock Analysis - Frequently Asked Questions

How have SKYE shares performed this year?

Skye Bioscience's stock was trading at $2.83 at the beginning of the year. Since then, SKYE stock has increased by 41.3% and is now trading at $4.00.

How were Skye Bioscience's earnings last quarter?

Skye Bioscience, Inc. (NASDAQ:SKYE) announced its quarterly earnings results on Thursday, August, 7th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by $0.10.
Read the conference call transcript.

Who are Skye Bioscience's major shareholders?

Skye Bioscience's top institutional investors include MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. (0.94%), Geode Capital Management LLC (0.65%), Marshall Wace LLP (0.34%) and Qube Research & Technologies Ltd (0.17%). Insiders that own company stock include Punit Dhillon, Paul A Grayson, Kaitlyn Arsenault, Tuan Tu Diep, Andrew J Schwab and 5Am Partners Vii, Llc.
View institutional ownership trends.

How do I buy shares of Skye Bioscience?

Shares of SKYE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Skye Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Skye Bioscience investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Netflix (NFLX), Tesla (TSLA) and Alphabet (GOOG).

Company Calendar

• Last Earnings: 8/07/2025
• Today: 9/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SKYE
• Previous Symbol: NASDAQ:SKYE
• CIK: 1516551
• Web: skyebioscience.com
• Phone: 858-410-0266
• Fax: N/A
• Employees: 11
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Skye Bioscience: $15.50
• High Price Target: $20.00
• Low Price Target: $10.00
• Potential Upside/Downside: +287.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.14
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.06)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$26.57 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -76.03%
• Return on Assets: -69.20%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.09
• Quick Ratio: 6.09

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.25 per share
• Price / Book: 1.78

Miscellaneous

• Outstanding Shares: 30,990,000
• Free Float: 29,594,000
• Market Cap: $123.96 million
• Optionable: Optionable
• Beta: 2.34